Dual bronchodilator therapy in COPD ‘may raise heart risk’
Prescribers need to bear this in mind considering the extra benefit is only modest,, researchers say
People with COPD who use two forms of long-acting bronchodilator concomitantly have more than a 50% higher risk of acute coronary syndrome than those who use a long-acting muscarinic antagonist (LAMA) alone, a study suggests.
“This is important because coronary events are responsible for more deaths than respiratory failure in patients with COPD,” the authors say.
In the case-control study, which utilised data from almost 30,000 patients with COPD from the PREDICT primary care cohort in New Zealand, 1490 patients had incident acute coronary syndrome (ACS) over follow-up from 2006 to 2016.
The patients with both COPD and ACS, aged between 45 and 84 years, were each matched with up to 10 other patients with COPD who did not develop ACS.
